Cargando…
Growth and Overall Health of Patients with SLC13A5 Citrate Transporter Disorder
We were interested in elucidating the non-neurologic health of patients with autosomal recessive SLC13A5 Citrate Transporter (NaCT) Disorder. Multiple variants have been reported that cause a loss of transporter activity, resulting in significant neurologic impairment, including seizures, as well as...
Autores principales: | Brown, Tanya L., Nye, Kimberly L., Porter, Brenda E. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8625967/ https://www.ncbi.nlm.nih.gov/pubmed/34822404 http://dx.doi.org/10.3390/metabo11110746 |
Ejemplares similares
-
Epilepsy and EEG Phenotype of SLC13A5 Citrate Transporter
Disorder
por: Yang, Qian-Zhou, et al.
Publicado: (2020) -
Characterizing a rare neurogenetic disease, SLC13A5 citrate transporter disorder, utilizing clinical data in a cloud-based medical record collection system
por: Spelbrink, Emily M., et al.
Publicado: (2023) -
The citrate transporters SLC13A5 and SLC25A1 elicit different metabolic responses and phenotypes in the mouse
por: Fernandez-Fuente, Gonzalo, et al.
Publicado: (2023) -
SLC13A5 Deficiency Disorder: From Genetics to Gene Therapy
por: Goodspeed, Kimberly, et al.
Publicado: (2022) -
Plasma Membrane Na(+)-Coupled Citrate Transporter (SLC13A5) and Neonatal Epileptic Encephalopathy
por: Bhutia, Yangzom D., et al.
Publicado: (2017)